Dr Constantia Pantelidou speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study which looked at the immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer (TNBC).

She reports that PARP inhibitors induce an anti-tumour immune response in BRCA1-deficient TNBC but not in BRCA1-proficient TNBC.

Dr Pantelidou explains that this T cell recruitment is mediated through activation of the STING pathway and this activation is sufficient for the anti-tumour immune response to PARP inhibitors.